FGEN Quote, Trading Chart, FibroGen Inc
home / stock / fgen / fgen quote
$29.09 Last:
1.01% Change Percent:
$29 Open:
$29.09 Previous Close:
$29.45 High:
$28.8 Low:
940,668 Volume:
06/24/2021 04:41:53 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
FGEN Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-24 | 29 | 29.09 | 29.45 | 28.8 | 940,668 |
| 2021-06-23 | 27.73 | 28.8 | 28.88 | 27.55 | 1,123,038 |
| 2021-06-22 | 27.6 | 27.65 | 28.04 | 27.19 | 717,701 |
| 2021-06-21 | 27.12 | 27.82 | 28.04 | 26.14 | 1,337,766 |
| 2021-06-18 | 25.82 | 26.96 | 26.99 | 25.82 | 1,402,418 |
| 2021-06-17 | 25.7 | 26.29 | 26.5 | 25.7 | 423,785 |
| 2021-06-16 | 25.3 | 25.84 | 25.92 | 25 | 732,898 |
| 2021-06-15 | 25.62 | 25.38 | 25.82 | 24.641 | 706,688 |
| 2021-06-14 | 26.03 | 25.82 | 26.51 | 25.43 | 844,362 |
| 2021-06-11 | 25.32 | 26.06 | 26.089 | 25 | 668,897 |
| 2021-06-10 | 24.62 | 25.15 | 25.23 | 24.18 | 594,324 |
| 2021-06-09 | 24.37 | 24.56 | 25.18 | 24.25 | 1,069,167 |
| 2021-06-08 | 22.96 | 24.11 | 24.47 | 22.17 | 1,066,896 |
| 2021-06-07 | 21.39 | 22.9 | 23.15 | 21.2 | 1,407,429 |
| 2021-06-04 | 21.19 | 21.15 | 21.42 | 20.65 | 390,718 |
| 2021-06-03 | 21.68 | 21.08 | 21.7302 | 21.05 | 553,488 |
| 2021-06-02 | 22.01 | 21.65 | 22.24 | 21.36 | 1,218,285 |
| 2021-06-01 | 21.5 | 21.83 | 22.23 | 21.24 | 824,486 |
| 2021-05-31 | 21.5 | 21.25 | 21.95 | 21.076 | 568,555 |
| 2021-05-28 | 21.5 | 21.25 | 21.95 | 21.076 | 568,455 |
News, Short Squeeze, Breakout and More Instantly...
-
FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs Transformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to Receive $25 Million Upfront, and Up to a Total of $1.1B ...
-
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adaptive trial platform evaluating pamrevlumab [and standard of care] for patien...
-
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - May 20, 2021) - Faruqi & Faruqi, LLP, a leading national securities law fir...